Hormone therapies for prostate cancer, such as abiraterone, GnRH agonists, GnRH antagonists, and enzalutamide, are associated with increased fluid retention or elevated blood pressure, which may lead to LLE [5–7]. The gene discussed is GNRH1; the disease is prostate carcinoma.